FDA approves Lupin NDA for SUPRAX Oral Suspension, 500 mg/5mL
News | 25 February 2013
PBR Staff Writer Published 25 February 2013. The US Food and Drug Administration (FDA) has approved Lupin Pharmaceuticals' new drug application (NDA) for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL. The new dosage strength is indicated for ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
